BEZ235 TosylateMTOR/P13K inhibitor CAS# 1028385-32-1 |
- BEZ235 Tosylate
Catalog No.:BCC1416
CAS No.:1028385-32-1
- GSK2126458
Catalog No.:BCC3884
CAS No.:1086062-66-9
- VS-5584 (SB2343)
Catalog No.:BCC2047
CAS No.:1246560-33-7
- Everolimus (RAD001)
Catalog No.:BCC3594
CAS No.:159351-69-6
- PIK-294
Catalog No.:BCC4995
CAS No.:900185-02-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1028385-32-1 | SDF | Download SDF |
| PubChem ID | 49803145 | Appearance | Powder |
| Formula | C37H31N5O4S | M.Wt | 641.74 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | NVP-BEZ 235 Tosylate | ||
| Solubility | DMSO : 34 mg/mL (52.98 mM; Need ultrasonic and warming) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | 4-methylbenzenesulfonic acid;2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile | ||
| SMILES | CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5 | ||
| Standard InChIKey | FWURTHAUPVXZHW-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C30H23N5O.C7H8O3S/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36;1-6-2-4-7(5-3-6)11(8,9)10/h4-17H,1-3H3;2-5H,1H3,(H,8,9,10) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | BEZ235 Tosylate is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. BEZ235 inhibits mTORC1 and mTORC2.In Vitro:NVP-BEZ235 is an imidazo[4,5-c]quinoline derivative that inhibits PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. The IC50s for PI3Kα, β, γ, δ are 4, 75, 7, 5 nM, respectively. It is also found to be as active against the mutant PI3KαE545K or PI3KαH1047R with IC50s of 5.7 and 4.6 nM, respectively. In human tumor cell lines, it is able to effectively and specifically block the dysfunctional activation of the PI3K pathway, inducing G1 arrest. PTEN-null cell lines PC3M and U87MG shows a dose-dependent reduction in cell proliferation when treated with increasing concentrations of NVP-BEZ235, with an average GI50 of 10 to 12 nM[1].In Vivo:NVP-BEZ235 is well tolerated, displays disease stasis when administered orally, and enhances the efficacy of other anticancer agents. At a dose of 50 mg/kg, NVP-BEZ235 appears rapidly in plasma with a Cmax of 1.68 μM at 0.5 h and a C24h of 0.03 μM[1]. References: | |||||
BEZ235 Tosylate Dilution Calculator
BEZ235 Tosylate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.5583 mL | 7.7913 mL | 15.5826 mL | 31.1653 mL | 38.9566 mL |
| 5 mM | 0.3117 mL | 1.5583 mL | 3.1165 mL | 6.2331 mL | 7.7913 mL |
| 10 mM | 0.1558 mL | 0.7791 mL | 1.5583 mL | 3.1165 mL | 3.8957 mL |
| 50 mM | 0.0312 mL | 0.1558 mL | 0.3117 mL | 0.6233 mL | 0.7791 mL |
| 100 mM | 0.0156 mL | 0.0779 mL | 0.1558 mL | 0.3117 mL | 0.3896 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
BEZ235 is an imidazoquinoline derivative inhibiting both PI3K and mTOR kinases with low nanomolar IC50s. It was well tolerated in preclinical animal studies as well as in clinical trials with manageable gastrointestinal side-effects[1, 2]. It competes with ATP by binding to the ATP-binding site of kinases and reversibly reduces enzyme activity, resulting in growth arrest of tumor cells in G1 phase[1]. Besides the inhibition of cell growth, BEZ235 blocks VEGF-induced angiogenesis[3]. It may also inhibit DNA-PKcs[4].
BEZ235 has shown potential anti-tumor activity both in vitro and in vivo. It inhibited growth of multiple cancer cell lines independently of mutation status in PI3K pathway[5]. In xenograft mice models, it blocked PI3K signaling and showed antitumor activity[1, 5]. Combination study demonstrated that it enhances the efficacy of temozolomide[1].
Clinical data shows anti-tumor activity of BEZ235 treatment, especially in cancer patients with deregulated PI3K signaling pathway. This compound is currently under investigation in multiple clinical trials either as monotherapy or in combination with other agents.
References:
1. Maira SM, Stauffer F, Brueggen J et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7: 1851-1863.
2. Markman B, Tabernero J, Krop I et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol 2012; 23: 2399-2408.
3. Schnell CR, Stauffer F, Allegrini PR et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 2008; 68: 6598-6607.
4. Mukherjee B, Tomimatsu N, Amancherla K et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia 2012; 14: 34-43.
5. Serra V, Markman B, Scaltriti M et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68: 8022-8030.
- VUF 10460
Catalog No.:BCC6285
CAS No.:1028327-66-3
- Dihydrocinchonamine
Catalog No.:BCN5841
CAS No.:10283-68-8
- RuBi-GABA
Catalog No.:BCC6012
CAS No.:1028141-88-9
- [D-p-Cl-Phe6,Leu17]-VIP
Catalog No.:BCC5968
CAS No.:102805-45-8
- GYKI 52466 dihydrochloride
Catalog No.:BCC7072
CAS No.:102771-26-6
- Levetiracetam
Catalog No.:BCC1056
CAS No.:102767-28-2
- PSB 0788
Catalog No.:BCC7599
CAS No.:1027513-54-7
- H-Gln(Trt)-OH
Catalog No.:BCC2919
CAS No.:102747-84-2
- VX-222 (VCH-222, Lomibuvir)
Catalog No.:BCC2108
CAS No.:1026785-59-0
- Labd-13-ene-8,15-diol
Catalog No.:BCN5840
CAS No.:10267-31-9
- LB-100
Catalog No.:BCC5532
CAS No.:1026680-07-8
- RO-3
Catalog No.:BCC7548
CAS No.:1026582-88-6
- D-Pinitol
Catalog No.:BCN5842
CAS No.:10284-63-6
- Mulberroside A
Catalog No.:BCN6343
CAS No.:102841-42-9
- Mulberroside C
Catalog No.:BCN6344
CAS No.:102841-43-0
- Moracin P
Catalog No.:BCN3289
CAS No.:102841-46-3
- Ganolactone B
Catalog No.:BCN2872
CAS No.:1028449-53-7
- MLN8237 (Alisertib)
Catalog No.:BCC2166
CAS No.:1028486-01-2
- Intermedine
Catalog No.:BCN1997
CAS No.:10285-06-0
- Lycopsamine
Catalog No.:BCN1999
CAS No.:10285-07-1
- 17-Hydroxy sprengerinin C
Catalog No.:BCN2755
CAS No.:1029017-75-1
- Pexidartinib (PLX3397)
Catalog No.:BCC6405
CAS No.:1029044-16-3
- MDL 73005EF hydrochloride
Catalog No.:BCC6636
CAS No.:102908-60-1
- Scutellaric acid
Catalog No.:BCN5843
CAS No.:102919-76-6
